ATE509924T1 - Neue salzform eines dopaminagonisten - Google Patents

Neue salzform eines dopaminagonisten

Info

Publication number
ATE509924T1
ATE509924T1 AT06701218T AT06701218T ATE509924T1 AT E509924 T1 ATE509924 T1 AT E509924T1 AT 06701218 T AT06701218 T AT 06701218T AT 06701218 T AT06701218 T AT 06701218T AT E509924 T1 ATE509924 T1 AT E509924T1
Authority
AT
Austria
Prior art keywords
salt form
dopamine agonist
new salt
new
dopamine
Prior art date
Application number
AT06701218T
Other languages
English (en)
Inventor
Stuart Peter Green
Olivier Alain Lazzari
Duncan Charles Miller
Fabrice Henri Salingue
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE509924T1 publication Critical patent/ATE509924T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
AT06701218T 2005-02-07 2006-01-26 Neue salzform eines dopaminagonisten ATE509924T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502509.3A GB0502509D0 (en) 2005-02-07 2005-02-07 Novel salt form of a dopamine agonist
PCT/IB2006/000222 WO2006082511A1 (en) 2005-02-07 2006-01-26 Novel salt form of a dopamine agonist

Publications (1)

Publication Number Publication Date
ATE509924T1 true ATE509924T1 (de) 2011-06-15

Family

ID=34355919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06701218T ATE509924T1 (de) 2005-02-07 2006-01-26 Neue salzform eines dopaminagonisten

Country Status (26)

Country Link
US (1) US7498329B2 (de)
EP (1) EP1848709B1 (de)
JP (1) JP4157158B2 (de)
KR (1) KR100997033B1 (de)
CN (1) CN101115737B (de)
AR (1) AR053122A1 (de)
AT (1) ATE509924T1 (de)
AU (1) AU2006211033A1 (de)
BR (1) BRPI0608149A2 (de)
CA (1) CA2595815C (de)
DO (1) DOP2006000030A (de)
ES (1) ES2364345T3 (de)
GB (1) GB0502509D0 (de)
GT (1) GT200600040A (de)
HN (1) HN2006004827A (de)
IL (1) IL184395A0 (de)
MX (1) MX2007008462A (de)
NL (1) NL1031087C2 (de)
NZ (1) NZ556292A (de)
PA (1) PA8662001A1 (de)
PE (1) PE20061034A1 (de)
RU (1) RU2393153C2 (de)
TW (1) TWI314930B (de)
UY (1) UY29365A1 (de)
WO (1) WO2006082511A1 (de)
ZA (1) ZA200605491B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8522799B2 (en) * 2005-12-30 2013-09-03 Lam Research Corporation Apparatus and system for cleaning a substrate
KR100913791B1 (ko) * 2006-07-21 2009-08-26 한미약품 주식회사 (s)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
CA3024216C (en) 2010-02-12 2021-03-30 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
KR20170090422A (ko) 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
RU2622018C1 (ru) * 2016-06-16 2017-06-08 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Быстро растворяющаяся трансбуккальная плёнка для лечения депрессивных расстройств, тревоги и расстройств адаптации

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052372A1 (en) * 2002-12-10 2004-06-24 Pfizer Limited Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EA200601982A1 (ru) * 2004-05-27 2007-04-27 Пфайзер Инк. Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов

Also Published As

Publication number Publication date
JP2008529997A (ja) 2008-08-07
HN2006004827A (es) 2010-06-09
JP4157158B2 (ja) 2008-09-24
NZ556292A (en) 2010-10-29
EP1848709A1 (de) 2007-10-31
KR100997033B1 (ko) 2010-11-26
WO2006082511A1 (en) 2006-08-10
RU2007130150A (ru) 2009-03-20
GB0502509D0 (en) 2005-03-16
ZA200605491B (en) 2008-09-25
ES2364345T3 (es) 2011-08-31
NL1031087C2 (nl) 2007-01-19
BRPI0608149A2 (pt) 2009-11-10
TWI314930B (en) 2009-09-21
AU2006211033A1 (en) 2006-08-10
CA2595815A1 (en) 2006-08-10
GT200600040A (es) 2007-01-12
IL184395A0 (en) 2007-10-31
CA2595815C (en) 2010-07-27
AR053122A1 (es) 2007-04-25
CN101115737B (zh) 2010-12-01
US7498329B2 (en) 2009-03-03
EP1848709B1 (de) 2011-05-18
MX2007008462A (es) 2007-07-25
RU2393153C2 (ru) 2010-06-27
DOP2006000030A (es) 2006-08-15
PE20061034A1 (es) 2006-10-19
TW200639164A (en) 2006-11-16
PA8662001A1 (es) 2006-09-08
KR20070094647A (ko) 2007-09-20
UY29365A1 (es) 2006-10-02
US20060183740A1 (en) 2006-08-17
CN101115737A (zh) 2008-01-30
NL1031087A1 (nl) 2006-08-08

Similar Documents

Publication Publication Date Title
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
DE602006018355D1 (de) Transdermale verabreichung eines meptazinolsalzes
FIC20150052I1 (fi) Kobisistaatti tai sen farmaseuttisesti hyväksyttävä suola
ATE414088T1 (de) Polymorphe formen eines gabaa-agonisten
DE602006008878D1 (de) Aufbau eines rotierenden Gleichrichters
DE602006002764D1 (de) Dekorative Mehrschichtabdeckung eines Radargeräts
ATE449068T1 (de) Neue mikrobiozide
DE602006007563D1 (de) Agonisten
DE602007003661D1 (de) Plattformflosse eines Gebläses
DE602006011123D1 (de) Führungsbewegung eines deckellosen einfüllstutzenverschlusses
ATE549333T1 (de) Neue sulfonylpyrrole als hdac-inhibitoren
DE602006003575D1 (de) Schwenkzylinder
ATE509924T1 (de) Neue salzform eines dopaminagonisten
ATE452535T1 (de) Neue antifungale zusammensetzung
DE112007000649A5 (de) Kolbenstangenanbindung
ATE531992T1 (de) Leitung eines spritzgestänges
DE112006002832A5 (de) Zylinderkopf
ATE459618T1 (de) 3-piperidinylisochroman-5-ole als dopaminagonisten
DE602006016728D1 (de) Innenteil eines festplattenlaufwerks
SE530154C8 (sv) Saltblandning
ATE549318T1 (de) Aminsalz eines carbostyrylderivates
ATE524461T1 (de) Neue substituierte piperidylpropanthiole
EP2015070A4 (de) Neuer marker für empfindlichkeit gegenüber einer sulfonamidverbindung
FI20055672A (fi) Sauvan tassu
DE602006008015D1 (de) Feste salzformen eines pyrrolsubstituierten 2-indolinons

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties